Special Issue "Rabies Vaccines and Immunoglobulins"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 8457
Interests: rabies; dog population ecology; zoonoses; epidemiology
Rabies is a typically fatal but vaccine-preventable disease caused by infection with rabies virus (RABV) and other members of the Lyssavirus family. Rabies vaccines and immunoglobulins are essential for the prevention and control of the disease in human and animal populations. In this Special Issue, we invite submissions of original research or review articles to highlight the state of the art and future directions in the development of these biologics. Our scope encompasses use in humans or animals, for pre- or post-exposure prophylaxis or treatment. Topics of interest include (but are not limited to) safety, immunogenicity, and efficacy of current and next-generation rabies vaccines and immunoglobulins; delivery strategies for pre-exposure prophylaxis for domestic animal, wildlife or human populations; cost-effectiveness studies; thermostability; novel adjuvants; non-specific effects of vaccines; preclinical, clinical. or post-marketing studies of new products, regimens, or routes of administration; use of recombinant monoclonal antibodies for post-exposure prophylaxis or treatment.
Prof. Dr. Darryn Knobel
Dr. Carlos Palacios
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pre-exposure prophylaxis
- post-exposure prophylaxis
- non-specific effects
- vaccine delivery
- monoclonal antibodies